optimizing the use of ipilimumab/nivolumab in mrcc
Published 5 years ago • 766 plays • Length 3:16Download video MP4
Download video MP3
Similar videos
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
4:46
sbrt in combination with ipilimumab/nivolumab in mrcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
8:43
optimizing the upfront treatment of metastatic renal cell carcinoma
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
2:00
nivolumab and ipilimumab in mrcc
-
7:31
conclusion: optimizing the treatment of renal cell carcinoma
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
2:36
safety and efficacy of nivolumab in mrcc: final analysis from the nivoren study
-
1:45
dr. kluger on the toxicity profile of concurrent nivolumab and ipilimumab
-
1:22
dr. sznol discusses the combination of ipilimumab and nivolumab in melanoma
-
1:30
targeted therapies for the treatment of mrcc after nivolumab-ipilimumab failure
-
1:34
dr. sharpless on managing toxicities with nivolumab/ipilimumab in melanoma
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc